Articles with public access mandates - kaustuv sahooLearn more
Not available anywhere: 4
Nanoparticle attachment to erythrocyte via the glycophorin a targeted ERY1 ligand enhances binding without impacting cellular function
K Sahoo, RSH Koralege, N Flynn, S Koteeswaran, P Clark, S Hartson, ...
Pharmaceutical research 33, 1191-1203, 2016
Mandates: US National Institutes of Health
Molecular and biocompatibility characterization of red blood cell membrane targeted and cell-penetrating-peptide-modified polymeric nanoparticles
K Sahoo, S Karumuri, RS Hikkaduwa Koralege, NH Flynn, S Hartson, ...
Molecular Pharmaceutics 14 (7), 2224-2235, 2017
Mandates: US Department of Defense
Synthesis and in vivo evaluation of Tc-99m-labeled cyclic CisoDGRC peptide conjugates for targeting αvβ3 integrin expression
G Pathuri, K Sahoo, V Awasthi, H Gali
Bioorganic & medicinal chemistry letters 20 (20), 5969-5972, 2010
Mandates: US National Institutes of Health
Erythrocytes internalize nanoparticles functionalized with low molecular weight protamine
RS Hikkaduwa Koralege, K Sahoo, N Flynn, J Liu, A Ranjan, C Pope, ...
Journal of Nanoparticle Research 23, 1-16, 2021
Mandates: US Department of Defense
Available somewhere: 10
CLEFMA—An anti-proliferative curcuminoid from structure–activity relationship studies on 3, 5-bis (benzylidene)-4-piperidones
P Lagisetty, P Vilekar, K Sahoo, S Anant, V Awasthi
Bioorganic & medicinal chemistry 18 (16), 6109-6120, 2010
Mandates: US National Institutes of Health
Cyclodextrin-mediated entrapment of curcuminoid 4-[3, 5-bis (2-chlorobenzylidene-4-oxo-piperidine-1-yl)-4-oxo-2-butenoic acid] or CLEFMA in liposomes for treatment of xenograft …
H Agashe, K Sahoo, P Lagisetty, V Awasthi
Colloids and Surfaces B: Biointerfaces 84 (2), 329-337, 2011
Mandates: US National Institutes of Health
Synthesis and characterisation of ultrasound imageable heat-sensitive liposomes for HIFU therapy
D Maples, K McLean, K Sahoo, R Newhardt, P Venkatesan, B Wood, ...
International Journal of Hyperthermia 31 (6), 674-685, 2015
Mandates: US National Institutes of Health
The curcuminoid CLEFMA selectively induces cell death in H441 lung adenocarcinoma cells via oxidative stress
K Sahoo, MG Dozmorov, S Anant, V Awasthi
Investigational new drugs 30, 558-567, 2012
Mandates: US National Institutes of Health
Remediation of hemorrhagic shock-induced intestinal barrier dysfunction by treatment with diphenyldihaloketones EF24 and CLEFMA
VR Yadav, A Hussain, K Sahoo, V Awasthi
Journal of Pharmacology and Experimental Therapeutics 351 (2), 413-422, 2014
Mandates: US National Institutes of Health
Liposome-encapsulated EF24-HPβCD inclusion complex: a preformulation study and biodistribution in a rat model
H Agashe, P Lagisetty, K Sahoo, D Bourne, B Grady, V Awasthi
Journal of Nanoparticle Research 13, 2609-2623, 2011
Mandates: US National Institutes of Health
Pharmacologic suppression of inflammation by a diphenyldifluoroketone, EF24, in a rat model of fixed-volume hemorrhage improves survival
VR Yadav, K Sahoo, PR Roberts, V Awasthi
Journal of Pharmacology and Experimental Therapeutics 347 (2), 346-356, 2013
Mandates: US National Institutes of Health
Preclinical evaluation of 4‐[3, 5‐bis (2‐chlorobenzylidene)‐4‐oxo‐piperidine‐1‐yl]‐4‐oxo‐2‐butenoic acid, in a mouse model of lung cancer xenograft
VR Yadav, K Sahoo, V Awasthi
British journal of pharmacology 170 (7), 1436-1448, 2013
Mandates: US National Institutes of Health
Anticancer Activity of an Imageable Curcuminoid 1‐[2‐Aminoethyl‐(6‐hydrazinopyridine‐3‐carbamidyl)‐3, 5‐bis‐(2‐fluorobenzylidene)‐4‐piperidone (EFAH)
P Lagisetty, D Subramaniam, K Sahoo, S Anant, V Awasthi
Chemical biology & drug design 79 (2), 194-201, 2012
Mandates: US National Institutes of Health
Differential oxidative and pro-apoptotic response of cancer and normal cells to an anti-inflammatory agent CLEFMA
K Sahoo, V Awasthi
bioRxiv, 2021.06. 02.446782, 2021
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program